# Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3

> **NCT04277338** · PHASE1 · COMPLETED · sponsor: **Tomsk National Research Medical Center of the Russian Academy of Sciences** · enrollment: 30 (actual)

## Conditions studied

- Primary Breast Cancer

## Interventions

- **DRUG:** SPECT

## Key facts

- **NCT ID:** NCT04277338
- **Lead sponsor:** Tomsk National Research Medical Center of the Russian Academy of Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-10
- **Primary completion:** 2021-02-10
- **Final completion:** 2021-10-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04277338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04277338, "Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04277338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*